AI Science Tracker

Virtual Lab: AI agents design nanobodies against SARS-CoV-2

CZ Biohub; and Stanford University · 29 Jul 2025 · biology

Discovery

Virtual Lab: AI agents design nanobodies against SARS-CoV-2

A group of AI agents led by a principal agent designed 92 nanobodies: two bound to spike protein from recent variants in lab tests, and humans wrote about 1% of the conversation. Only 2 of 92 bound; the date is the Nature publication date given on the page.

Technology: Multiple AI agents (Virtual Lab)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: The Virtual Lab designed 92 nanobodies; experiments (multiplexed ELISA) showed a range of functional binders. Two showed improved binding to JN.1 or KP.3 while keeping strong binding to the ancestral spike protein.
  • Still unknown: The two are called candidates for further investigation. Neutralization and clinical use not reported in the abstract. Full text is paywalled; counts of tested designs beyond 92 and binding values were not read.
  • AI role: An LLM principal investigator agent guided LLM scientist agents through meetings, with human feedback; they built a pipeline using ESM, AlphaFold-Multimer and Rosetta. Humans ran the experiments.

Evidence sources: https://doi.org/10.1038/s41586-025-09442-9

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 388 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.